Wave Life Sciences Ltd. - Ordinary Shares (WVE): Price and Financial Metrics
GET POWR RATINGS... FREE!
WVE POWR Grades
- WVE scores best on the Growth dimension, with a Growth rank ahead of 57.96% of US stocks.
- WVE's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
- WVE ranks lowest in Momentum; there it ranks in the 5th percentile.
WVE Stock Summary
- Of note is the ratio of Wave Life Sciences Ltd's sales and general administrative expense to its total operating expenses; merely 12.11% of US stocks have a lower such ratio.
- WVE's price/sales ratio is 19.7; that's higher than the P/S ratio of 90.16% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for WVE comes in at -50.62% -- higher than that of only 5.33% of stocks in our set.
- Stocks that are quantitatively similar to WVE, based on their financial statements, market capitalization, and price volatility, are IMGN, ABUS, ASMB, PLRX, and IDYA.
- WVE's SEC filings can be seen here. And to visit Wave Life Sciences Ltd's official web site, go to www.wavelifesciences.com.
WVE Valuation Summary
- In comparison to the median Healthcare stock, WVE's EV/EBIT ratio is 104.78% lower, now standing at -1.4.
- WVE's price/sales ratio has moved down 2247.9 over the prior 71 months.
- Over the past 71 months, WVE's price/sales ratio has gone down 2247.9.
Below are key valuation metrics over time for WVE.
WVE's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- WVE has a Quality Grade of C, ranking ahead of 32.84% of graded US stocks.
- WVE's asset turnover comes in at 0.06 -- ranking 309th of 677 Pharmaceutical Products stocks.
- IONS, CORT, and CPIX are the stocks whose asset turnover ratios are most correlated with WVE.
The table below shows WVE's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
WVE Stock Price Chart Interactive Chart >
WVE Price/Volume Stats
|Current price||$6.18||52-week high||$12.17|
|Prev. close||$6.08||52-week low||$4.82|
|Day high||$6.32||Avg. volume||658,786|
|50-day MA||$5.98||Dividend yield||N/A|
|200-day MA||$7.51||Market Cap||313.73M|
Wave Life Sciences Ltd. - Ordinary Shares (WVE) Company Bio
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company was founded in 2012 and is based in Simgapore.
Most Popular Stories View All
WVE Latest News Stream
|Loading, please wait...|
WVE Latest Social Stream
View Full WVE Social Stream
Latest WVE News From Around the Web
Below are the latest news stories about Wave Life Sciences Ltd that investors may wish to consider to help them evaluate WVE as an investment opportunity.
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan Virtual Genetic Medicines Conference on Monday, October 4, 2021 at 2:00 p.m. ET. A live webcast of the presentation wi
In this article, we will take a look at 10 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie. You can skip our detailed analysis of Lee Ainslie’s history, investment strategy, and hedge fund performance, and go directly to see the 5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire […]
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntingtons Disease
Only clinical-stage candidate for Huntingtons disease designed to selectively lower mutant HTT and spare wild-type HTT
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
Only clinical-stage candidate for Huntington’s disease designed to selectively lower mutant HTT and spare wild-type HTT Adaptive trial design to enable faster optimization of dosing and decision-making on next steps for WVE-003; data to be generated through 2022 WVE-003 preclinical data and SELECT-HD trial to be highlighted at EHDN 2021 Remote Meeting September 9-11, 2021 CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicine
Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT
WVE Price Returns